Piramal Pharma Limited
NSE: PPLPHARMA BSE: PPLPHARMA
Prev Close
190.75
Open Price
189
Volume
2,767,111
Today Low / High
187.31 / 194.85
52 WK Low / High
114.35 / 307.9
Range
183 - 202
Prev Close
190.7
Open Price
190.55
Volume
159,942
Today Low / High
187.2 / 194.75
52 WK Low / High
114.45 / 307.85
Range
183 - 202
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 192.11 (target range: 183 - 202), reflecting a change of 1.36 (0.71298%). On the BSE, it is listed at 192.5 (target range: 183 - 202), showing a change of 1.8 (0.94389%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Piramal Pharma Limited Graph
Piramal Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking Target Price for Piramal Pharma Limited T1, T2, T3, for both Bullish or Bearish. For Bullish T1, T2, T3 and for Bearish T1, T2, T3. The stock current price is 192, with potential price targets ranging from T1, T2, T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 192.50 | 194.43 | 174.98 - 213.87 |
| 196.35 | 157.08 - 235.62 | ||
| 198.28 | 138.79 - 257.76 | ||
| Bearish Scenario | 192.50 | 190.58 | 171.52 - 209.63 |
| 188.65 | 150.92 - 226.38 | ||
| 186.73 | 130.71 - 242.74 |
Overview of Piramal Pharma Limited
ISIN
INE0DK501011
Industry
Biotechnology
Vol.Avg
7,379,268
Market Cap
254,543,654,400
Last Dividend
0.11
Official Website
IPO Date
2022-10-19
DCF Diff
353.80
DCF
-163
Financial Ratios Every Investor Needs
Stock Dividend of PPLPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-12 | July 12, 24 | 0.11 | 0.11 | 2024-07-12 | 2024-08-25 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 8,171.16 Cr | 3,261.71 Cr | 4,909.45 Cr | 0.6008 | 100.67 Cr | 262.75 Cr | 431.51 Cr | 17.82 Cr | 0.14 | 1,366.81 Cr | 0.0022 |
| 2023-03-31 | 7,081.55 Cr | 2,703.30 Cr | 4,378.25 Cr | 0.6183 | 86.36 Cr | 231.69 Cr | 14.15 Cr | -186.46 Cr | -1.53 | 846.35 Cr | -0.0263 |
| 2022-03-31 | 3,095.35 Cr | 1,549.13 Cr | 1,546.22 Cr | 0.4995 | 61.94 Cr | 60.78 Cr | 560.20 Cr | 375.96 Cr | 3.11 | 1,210.38 Cr | 0.1215 |
| 2021-03-31 | 2,938.81 Cr | 1,278.31 Cr | 1,660.50 Cr | 0.5650 | 69.14 Cr | 53.85 Cr | 550.39 Cr | 571.50 Cr | 4.68 | 611.35 Cr | 0.1945 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 356.82 Cr | 15,311.81 Cr | 7,400.44 Cr | 7,911.3700 Cr | 4,710.16 Cr | 4,353.34 Cr | 2,175.88 Cr | 4,815.96 Cr | 343.62 Cr | 0.00 Cr | 240.26 Cr | 4,369.3000 Cr |
| 2023-03-31 | 195.59 Cr | 14,522.56 Cr | 7,749.06 Cr | 6,773.5000 Cr | 5,637.08 Cr | 5,441.49 Cr | 1,681.37 Cr | 4,441.45 Cr | 269.80 Cr | 25.66 Cr | 211.87 Cr | 3,843.0500 Cr |
| 2022-03-31 | 84.65 Cr | 7,208.32 Cr | 2,140.98 Cr | 5,067.4400 Cr | 1,111.38 Cr | 1,026.73 Cr | 481.28 Cr | 1,465.24 Cr | 235.02 Cr | 2,633.28 Cr | 216.77 Cr | 1,517.1400 Cr |
| 2021-03-31 | 146.73 Cr | 5,756.67 Cr | 1,656.05 Cr | 4,100.6200 Cr | 174.26 Cr | 27.53 Cr | 420.88 Cr | 1,384.57 Cr | 714.22 Cr | 0.00 Cr | 1,575.88 Cr | 1,471.6700 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,004.5400 Cr | -456.0600 Cr | -422.3600 Cr | 292.5000 Cr | 165.9600 Cr | 219.1900 Cr | -712.0400 Cr | 17.8200 Cr | -971.5300 Cr | 0.0000 Cr | -531.7500 Cr |
| 2023-03-31 | 483.8900 Cr | -1,338.7800 Cr | 817.7900 Cr | -480.8600 Cr | -31.9500 Cr | 53.2300 Cr | -964.7500 Cr | -167.5200 Cr | 1,198.4200 Cr | -67.0000 Cr | -172.6400 Cr |
| 2022-03-31 | 255.2000 Cr | -1,223.0200 Cr | 905.7400 Cr | 54.6900 Cr | -62.0800 Cr | 84.6500 Cr | -200.5100 Cr | 436.7000 Cr | 1,019.1300 Cr | -50.0000 Cr | -60.3300 Cr |
| 2021-03-31 | 34.7200 Cr | -4,382.8900 Cr | 4,494.1600 Cr | -23.3900 Cr | 145.9900 Cr | 146.7300 Cr | -58.1100 Cr | 349.1100 Cr | 90.3800 Cr | 0.0000 Cr | 95.3600 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 2,204.22 Cr | 805.83 Cr | 1,398.39 Cr | 0.6344 | 0.00 Cr | 3.68 Cr | 0.03 | 366.92 Cr | 0.0017 |
| 2024-09-30 | 2,241.75 Cr | 1,548.22 Cr | 693.53 Cr | 0.3094 | 149.39 Cr | 22.59 Cr | 0.17 | 419.98 Cr | 0.0101 |
| 2024-06-30 | 1,951.14 Cr | 1,438.61 Cr | 512.53 Cr | 0.2627 | 19.94 Cr | -88.64 Cr | -0.67 | 224.03 Cr | -0.0454 |
| 2024-03-31 | 2,552.36 Cr | 1,704.67 Cr | 847.69 Cr | 0.3321 | 333.80 Cr | 101.27 Cr | 0.77 | 525.79 Cr | 0.0397 |
| 2023-12-31 | 1,958.57 Cr | 675.15 Cr | 1,283.42 Cr | 0.6553 | 157.51 Cr | 10.11 Cr | 0.08 | 297.61 Cr | 0.0052 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 270.30 Cr | 182.48 Cr | 452.78 Cr | 1,827.14 Cr | 2,447.43 Cr | 5,381.66 Cr | 4,918.75 Cr | 15,241.74 Cr | 7,334.57 Cr |
| 2024-06-30 | -501.51 Cr | 1,003.02 Cr | 501.51 Cr | 0.00 Cr | 0.00 Cr | 501.51 Cr | 0.00 Cr | 0.00 Cr | -7,911.37 Cr |
| 2024-03-31 | 482.56 Cr | 144.69 Cr | 627.25 Cr | 2,134.80 Cr | 2,175.88 Cr | 5,464.47 Cr | 4,815.97 Cr | 15,311.81 Cr | 7,400.44 Cr |
| 2023-12-31 | -595.12 Cr | 1,190.24 Cr | 595.12 Cr | 0.00 Cr | 0.00 Cr | 595.12 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 251.50 Cr | 413.81 Cr | 665.31 Cr | 1,743.38 Cr | 2,060.47 Cr | 4,954.02 Cr | 4,691.26 Cr | 14,775.69 Cr | 7,017.83 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | -88.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 101.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 10.11 Cr | 372.64 Cr | 0.00 Cr | 0.00 Cr | 372.64 Cr | 908.62 Cr | 535.98 Cr | 0.00 Cr | 372.64 Cr |
| 2023-09-30 | 5.02 Cr | 369.02 Cr | 0.00 Cr | 0.00 Cr | 369.02 Cr | 535.98 Cr | 166.96 Cr | 0.00 Cr | 369.02 Cr |
| 2023-06-30 | -98.58 Cr | 347.22 Cr | 0.00 Cr | 0.00 Cr | 597.79 Cr | 651.02 Cr | 53.23 Cr | 0.00 Cr | 347.22 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-08-02 | August 02, 23 | 1023:1000 |
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹312.20 | ₹374,827,320,000.00 | ₹2,116,013.00 |
| Syngene International Limited | SYNGENE | ₹650.00 | ₹260,840,646,950.00 | ₹202,178.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹192.10 | ₹254,676,229,220.00 | ₹2,764,417.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,643.45 | ₹171,931,493,890.00 | ₹251,710.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹789.00 | ₹136,864,216,380.00 | ₹388,513.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹600.75 | ₹95,688,060,750.00 | ₹358,426.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹614.80 | ₹49,480,825,440.00 | ₹242,967.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹204.72 | ₹32,096,615,760.00 | ₹205,540.00 |
| Zota Health Care Limited | ZOTA | ₹812.25 | ₹22,261,823,100.00 | ₹42,771.00 |
Key Executives
Gender: male
Year Born: 1978
Gender: male
Year Born: 1973
Gender: male
Year Born: 1975
Gender: Not Specified
Year Born: 1964
Gender: male
Year Born: 1967
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born: 1973
Gender: female
Year Born:
Gender: female
Year Born: 1980
FAQs about Piramal Pharma Limited
The CEO is Mr. Peter Daniel DeYoung.
The current price is ₹192.00.
The range is ₹114.35-307.9.
The market capitalization is ₹25,454.37 crores.
The dividend yield is 0.06%.
The P/E ratio is 605.45.
The company operates in the Healthcare sector.
Overview of Piramal Pharma Limited (ISIN: INE0DK501011) is a leading Biotechnology in India. With a market capitalization of ₹25,454.37 crores and an average daily volume of 7,379,268 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.11.